Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy.
Peripheral insulin action and cellular insulin binding were studied in 10 newly detected, obese, black, Southern African women with Type 2 diabetes mellitus before and after mid-term oral sulphonylurea therapy and in five obese, non-diabetic controls. Glucose disposal (assessed by the euglycaemic insulin clamp technique) was significantly reduced in diabetic patients compared to control subjects (4.4 +/- 0.5 vs 6.4 +/- 0.5 mg kg-1 min-1, p < 0.05), and increased after 1 and 3 months of sulphonylurea therapy to 6.8 +/- 0.6 mg kg-1 min-1 (p = 0.01) and 6.3 +/- 0.7 mg kg-1 min-1 (p = 0.04), respectively. The major change in the binding kinetics of insulin to peripheral monocytes was an increase in the mean receptor concentration in the diabetic patients which was significant after 3 months of therapy (0.2 +/- 0.08 to 0.6 +/- 0.01 nM, p = 0.05). The basal plasma C-peptide concentration was significantly lower in the diabetic patients than in the controls and remained so following sulphonylurea therapy, despite significant reductions in fasting glucose and HbA1 concentrations. We conclude that newly diagnosed, obese, black Southern Africans with Type 2 diabetes showed diminished peripheral glucose disposal which increased following sulphonylurea therapy. This was accompanied by an increase in insulin receptor concentration but not with changes in basal insulin secretion.
Wing
J R
JR
Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Panz
V R
VR
Joffe
B I
BI
Seftel
H C
HC
D000328:Adult; D000704:Analysis of Variance; D001667:Binding, Competitive; D044383:Black People; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D015309:Glucose Clamp Technique; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives / Q000097:blood; D007700:Kinetics; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D009765:Obesity; D011374:Progesterone / Q000097:blood; D011972:Receptor, Insulin / Q000378:metabolism*; D013019:South Africa
D001786:Blood Glucose; D002096:C-Peptide; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007328:Insulin; D011374:Progesterone; D011972:Receptor, Insulin; C008147:insulin, iodo-